{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:07:17Z","timestamp":1793210837880,"version":"4.5.0"},"reference-count":307,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.autrev.2023.103312","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:18:50Z","timestamp":1678853930000},"page":"103312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders"],"prefix":"10.1016","volume":"22","author":[{"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schefzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Wiestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svjetlana","family":"Lovric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Hufendiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0005","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00005072-195312040-00005","article-title":"Experimental allergic encephalomyelitis during and following cortone acetate treatment","author":"Ferraro","year":"1953","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.autrev.2023.103312_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1749-6632.1965.tb20230.x","article-title":"Large dose corticosteroid therapy of experimental and human demyelinating diseases","volume":"122","author":"Kibler","year":"1965","journal-title":"Ann N Y Acad Sci"},{"issue":"3563","key":"10.1016\/j.autrev.2023.103312_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.140.3563.186","article-title":"Methotrexate: suppression of experimental allergic encephalomyelitis","volume":"140","author":"Brandriss","year":"1963","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0020","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0002-9343(66)90086-6","article-title":"Azathioprine therapy of \u201cautoimmune\u201d diseases","volume":"41","author":"Corley","year":"1966","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0025","first-page":"78","article-title":"Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use","volume":"77","author":"Emmons","year":"1987","journal-title":"Iowa Med"},{"issue":"14","key":"10.1016\/j.autrev.2023.103312_bb0030","article-title":"\u2018Multiple Sclerosis Therapy Consensus Group\u2019 (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"18","author":"Wiendl","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2015.02.004","article-title":"Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients","volume":"4","author":"Chouhfeh","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0040","first-page":"259","article-title":"Stwardnienie rozsiane a inne choroby autoimmunologiczne [Multiple sclerosis and other autoimmune diseases]","volume":"41","author":"Belniak","year":"2007","journal-title":"Neurol Neurochir Pol."},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0045","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00415-012-6790-1","article-title":"Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis","volume":"260","author":"Dobson","year":"2013","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0050","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1191\/1352458505ms1239oa","article-title":"Autoimmune hepatitis and multiple sclerosis: a coincidental association?","volume":"11","author":"de Seze","year":"2005","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0060","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029637","article-title":"The Interleukin (IL)-23\/T helper (Th)17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis","volume":"8","author":"Hiltensperger","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2023.103312_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jns.2014.01.003","article-title":"Multiple sclerosis is associated with psoriasis","volume":"338","author":"Fellner","year":"2014","journal-title":"A case-control study. J Neurol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol"},{"issue":"14","key":"10.1016\/j.autrev.2023.103312_bb0075","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0085","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01796261","article-title":"Leflunomide interferes with pyrimidine nucleotide biosynthesis","volume":"44","author":"Cherwinski","year":"1995","journal-title":"Inflamm Res"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","article-title":"Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases","volume":"8","author":"Fragoso","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0095","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1021\/jm301848w","article-title":"On dihydroorotate dehydrogenases and their inhibitors and uses","volume":"56","author":"Munier-Lehmann","year":"2013","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-2952(95)00255-X","article-title":"Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide","volume":"50","author":"Greene","year":"1995","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0105","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0304-4165(79)90131-4","article-title":"Conversion of dihydroorotate to orotate in parasitic protozoa","volume":"582","author":"Gutteridge","year":"1979","journal-title":"Biochim Biophys Acta"},{"issue":"9149","key":"10.1016\/j.autrev.2023.103312_bb0110","first-page":"259","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial","volume":"353","author":"Smolen","year":"1999","journal-title":"European Leflunomide Study Group. Lancet"},{"issue":"21","key":"10.1016\/j.autrev.2023.103312_bb0115","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","article-title":"Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group","volume":"43","author":"Sharp","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0125","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.autrev.2023.103312_bb0130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2023.103312_bb0135","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10928-005-0049-8","article-title":"Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis","volume":"32","author":"Shi","year":"2005","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0140","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sj\u00f6gren\u2019s syndrome: a phase II pilot study","volume":"66","author":"van Woerkom","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0145","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/annrheumdis-2011-201026","article-title":"Clinical efficacy of leflunomide in primary Sjogren\u2019s syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor \u03b1 expression","volume":"71","author":"Bikker","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0150","doi-asserted-by":"crossref","first-page":"E260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0155","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10067-014-2548-8","article-title":"The effect of leflunomide on the eye dryness in secondary Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients","volume":"33","author":"Shahin","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus."},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144548","article-title":"The efficacy and safety of leflunomide for the treatment of lupus nephritis in chinese patients: systematic review and meta-analysis","volume":"10","author":"Cao","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0170","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2003.019174","article-title":"Six months open label trial of leflunomide in active ankylosing spondylitis","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0175","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1136\/ard.2005.036491","article-title":"Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis","volume":"64","author":"van Denderen","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0180","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"German Network of Rheumatic Diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/keh009","article-title":"Maintenance of remission with leflunomide in Wegener\u2019s granulomatosis","volume":"43","author":"Metzler","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","article-title":"Canadian Vasculitis Research Network (CanVasc) and Vasculitis Clinical Research Consortium (VCRC). Efficacy of leflunomide in the treatment of vasculitis","volume":"39","author":"Mustapha","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/03009742.2019.1575980","article-title":"Leflunomide versus methotrexate in treatment of giant cell arteritis: comparison of efficacy, safety, and drug survival","volume":"48","author":"Tengesdal","year":"2019","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0200","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10067-018-4232-x","article-title":"Does leflunomide have a role in giant cell arteritis? An open-label study","volume":"38","author":"Ho\u010devar","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.rbr.2015.09.007","article-title":"Leflunomide in Takayasu arteritis - A long term observational study","volume":"56","author":"de Souza","year":"2016","journal-title":"Rev Bras Reumatol Engl Ed"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/03009742.2011.633553","article-title":"Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study","volume":"41","author":"de Souza","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0215","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/nep.12175","article-title":"Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria","volume":"19","author":"Zhang","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124352","article-title":"Clinical features of children with pulmonary microscopic polyangiitis: report of 9 cases","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0230","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00124743-200112000-00003","article-title":"Open trial of leflunomide for refractory psoriasis and psoriatic arthritis","volume":"7","author":"Liang","year":"2001","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0235","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2133.2004.05836.x","article-title":"Leflunomide in the treatment of psoriasis: results of a phase II open trial","volume":"150","author":"Tlacuilo-Parra","year":"2004","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00124743-200210000-00015","article-title":"Leflunomide in psoriatic polyarthritis","volume":"8","author":"Scarpa","year":"2002","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb0245","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/archderm.140.10.1288","article-title":"Leflunomide in psoriasis and psoriatic arthritis: a preliminary study","volume":"140","author":"Thami","year":"2004","journal-title":"Arch Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103312_bb0250","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10067-013-2315-2","article-title":"Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Molina","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0255","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/03009742.2015.1013983","article-title":"Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis","volume":"44","author":"Bichler","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0260","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0265","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458511421054","article-title":"Effect of BG-12 on contrast-enhanced lesions in patients with relapsing\u2014remitting multiple sclerosis: subgroup analyses from the phase 2b study","volume":"18","author":"Kappos","year":"2012","journal-title":"Mult Scler."},{"issue":"9648","key":"10.1016\/j.autrev.2023.103312_bb0270","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0275","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1-Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch Toxicol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0280","first-page":"103","article-title":"Heilung von Psoriasis vulgaris [Treatment of psoriasis vulgaris]","volume":"13","author":"Schweckendiek","year":"1959","journal-title":"Med Monatsschr."},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0290","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm\u00ae - and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0295","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb0300","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/ph13100306","article-title":"Dimethyl fumarate and its esters: a drug with broad clinical utility?","volume":"13","author":"Kourakis","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0305","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bjd.14698","article-title":"Severe recalcitrant cutaneous manifestations in systemic lupus erythematosus successfully treated with fumaric acid esters","volume":"176","author":"Saracino","year":"2017","journal-title":"Br J Dermatol."},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0310","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/0961203316644335","article-title":"Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study","volume":"25","author":"Kuhn","year":"2016","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0315","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2133.2005.06762.x","article-title":"Fumaric acid esters in necrobiosis lipoidica: results of a prospective noncontrolled study","volume":"153","author":"Kreuter","year":"2005","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000083514","article-title":"Disseminated granuloma annulare\u2014treatment with fumaric acid esters","volume":"210","author":"Eberlein-K\u00f6nig","year":"2005","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0325","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archopht.125.4.569","article-title":"Improvement of noninfectious uveitis with fumaric acid esters: results of a pilot study","volume":"125","author":"Heinz","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"Pt B","key":"10.1016\/j.autrev.2023.103312_bb0330","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","article-title":"Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases","volume":"113","author":"O\u2019Sullivan","year":"2017","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0335","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"issue":"10306","key":"10.1016\/j.autrev.2023.103312_bb0340","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0345","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","article-title":"Ponesimod: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.autrev.2023.103312_bb0350","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0355","article-title":"Ozanimod Treatment for Ulcerative Colitis","volume":"375","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0360","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0365","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann","year":"2019","journal-title":"Lupus Sci Med"},{"issue":"9959","key":"10.1016\/j.autrev.2023.103312_bb0375","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0380","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12969-019-0361-2","article-title":"Biologics in refractory myositis: experience in juvenile vs. adult myositis; part II: emerging biologic and other therapies on the horizon","volume":"17","author":"Patwardhan","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0385","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00003088-200039010-00002","article-title":"Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies","volume":"39","author":"Johnson","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0390","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb0395","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.26287","article-title":"The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience","volume":"96","author":"Broccoli","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0400","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/03009749709065702","article-title":"The safety profile of low-dose cladribine in refractory rheumatoid arthritis","volume":"26","author":"Schirmer","year":"1997","journal-title":"A pilot trial. Scand J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103312_bb0405","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.1780381112","article-title":"Oral 2-chlorodeoxyadenosine in psoriatic arthritis","volume":"38","author":"Eibschutz","year":"1995","journal-title":"A preliminary report. Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0410","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/1529-0131(199802)41:2<335::AID-ART18>3.0.CO;2-O","article-title":"A pilot study of 2-chloro-2\u2019-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis","volume":"41","author":"Davis","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2023.103312_bb0415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/10428194.2011.565435","article-title":"Hairy cell leukemia diagnostic criteria and differential diagnosis","volume":"52","author":"Summers","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0420","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00277-020-04349-z","article-title":"Skin changes in hairy cell leukemia","volume":"100","author":"Robak","year":"2021","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0425","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0002-9394(14)70543-4","article-title":"Ocular manifestation of hairy cell leukemia with dramatic response to 2-chloro-deoxy-adenosine","volume":"121","author":"Robinson","year":"1996","journal-title":"Am J Ophthalmol"},{"issue":"9139","key":"10.1016\/j.autrev.2023.103312_bb0430","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group","volume":"352","year":"1998","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0435","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0440","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.autrev.2023.103312_bb0445","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJM199711273372207","article-title":"Management of multiple sclerosis","volume":"337","author":"Rudick","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0450","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0455","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/ar598","article-title":"Interferon-beta for treatment of rheumatoid arthritis?","volume":"4","author":"van Holten","year":"2002","journal-title":"Arthritis Res"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0460","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/rheumatology\/38.4.362","article-title":"The effects of interferon beta treatment on arthritis","volume":"38","author":"Tak","year":"1999","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0465","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/ar1026","article-title":"A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]","volume":"6","author":"Genovese","year":"2004","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0470","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2003.020347","article-title":"A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis","volume":"64","author":"van Holten","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0475","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/ard.2010.141077","article-title":"Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis","volume":"70","author":"Corr","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0480","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14712598.4.4.469","article-title":"Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders","volume":"4","author":"Tilg","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0485","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/gut.2010.226860","article-title":"Suppression of inflammation in ulcerative colitis by interferon-\u03b2-1a is accompanied by inhibition of IL-13 production","volume":"60","author":"Mannon","year":"2011","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0490","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1055\/s-2007-963378","article-title":"Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial","volume":"45","author":"Musch","year":"2007","journal-title":"Z Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0495","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0500","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2023.103312_bb0505","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-230X-9-22","article-title":"Interferon beta-1a for the maintenance of remission in patients with Crohn\u2019s disease: results of a phase II dose-finding study","volume":"9","author":"Pena Rossi","year":"2009","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0510","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2036.2008.03778.x","article-title":"Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis","volume":"28","author":"Pena-Rossi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0515","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ajo.2013.05.002","article-title":"Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial","volume":"156","author":"Mackensen","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0520","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/09273948.2015.1125508","article-title":"Multiple Sclerosis-related Uveitis: Does MS Treatment Affect Uveitis Course?","volume":"25","author":"Jouve","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0525","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-\u03b2 exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb0530","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"9700","key":"10.1016\/j.autrev.2023.103312_bb0535","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0540","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ana.22316","article-title":"Phase III dose-comparison study of glatiramer acetate for multiple sclerosis","volume":"69","author":"Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M","year":"2011","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0545","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","article-title":"Randomized study combining interferon and glatiramer acetate in multiple sclerosis","volume":"73","author":"Lublin","year":"2013","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0550","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0555","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.nurt.2007.08.002","article-title":"Mechanism of action of glatiramer acetate in treatment of multiple sclerosis","volume":"4","author":"Weber","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0560","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.semarthrit.2013.11.007","article-title":"Coexistence of systemic lupus erythematosus and multiple sclerosis: prevalence, clinical characteristics, and natural history","volume":"43","author":"Fanouriakis","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0565","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oftal.2016.11.018","article-title":"Efficacy of immunomodulatory therapy with interferon-\u03b2 or glatiramer acetate on multiple sclerosis-associated uveitis","volume":"92","author":"Velazquez-Villoria","year":"2017","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0570","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"issue":"17","key":"10.1016\/j.autrev.2023.103312_bb0575","first-page":"1694","article-title":"Ocrelizumab in primary progressive and relapsing multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0580","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0585","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.autrev.2023.103312_bb0590","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0595","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.33353","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight\u2013week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Tak","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0600","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0605","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/art.33317","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Rigby","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"101","key":"10.1016\/j.autrev.2023.103312_bb0610","doi-asserted-by":"crossref","first-page":"101ra92","DOI":"10.1126\/scitranslmed.3002432","article-title":"A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis","volume":"3","author":"Owczarczyk","year":"2011","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0615","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"Taylor","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157961","article-title":"Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials","volume":"11","author":"Quattrocchi","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0625","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"Kurrasch","year":"2013","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0630","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"17","key":"10.1016\/j.autrev.2023.103312_bb0635","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/TCRM.S252592","article-title":"Emerging B-Cell Therapies in Systemic Lupus Erythematosus","volume":"14","author":"Bag-Ozbek","year":"2021","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0640","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13413","article-title":"Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child","volume":"23","author":"Solomon","year":"2019","journal-title":"Pediatr Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0645","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podest\u00e0","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0650","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0655","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ckj\/sfw022","article-title":"Ofatumumab treatment in lupus nephritis patients","volume":"9","author":"Haarhaus","year":"2016","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0660","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0961203320981137","article-title":"Ofatumumab use in juvenile systemic lupus erythematosus: A single centre experience","volume":"30","author":"Cinar","year":"2021","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0665","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12969-018-0278-1","article-title":"Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C \u03b4","volume":"16","author":"Lei","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"13","key":"10.1016\/j.autrev.2023.103312_bb0670","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMc1308488","article-title":"Ofatumumab for rituximab-resistant nephrotic syndrome","volume":"370","author":"Basu","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0675","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/rheumatology\/kew199","article-title":"Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series","volume":"55","author":"McAdoo","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0680","first-page":"20","article-title":"B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis","volume":"10","author":"Lundberg","year":"2017","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0685","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0690","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0695","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa057","article-title":"First case of refractory colitis caused by ocrelizumab","volume":"26","author":"Sunjaya","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"2020","key":"10.1016\/j.autrev.2023.103312_bb0700","first-page":"8858378","article-title":"Ocrelizumab-Induced Severe Colitis","volume":"7","author":"Lee","year":"2020","journal-title":"Case Rep Gastrointest Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0705","first-page":"447","article-title":"Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis","volume":"34","author":"Barnes","year":"2021","journal-title":"Ann Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0710","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/00365521.2020.1854847","article-title":"Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018","volume":"56","author":"Kristj\u00e1nsson","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0715","first-page":"38","article-title":"Natalizumab: overview of its pharmacology and safety","volume":"7","author":"Baker","year":"2007","journal-title":"Rev Gastroenterol Disord"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0720","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0725","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb0730","first-page":"CD007621","article-title":"Natalizumab for relapsing remitting multiple sclerosis","author":"Pucci","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"10.1016\/j.autrev.2023.103312_bb0735","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"International Efficacy of Natalizumab as Active Crohn\u2019s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0740","first-page":"CD006097","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0745","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","article-title":"Natalizumab for active Crohn\u2019s disease","volume":"348","author":"Ghosh","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0750","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1002\/ibd.21716","article-title":"Natalizumab to kill two birds with one stone: a case of celiac disease and multiple sclerosis","volume":"17","author":"Phan-Ba","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0755","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0760","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ecco-jcc\/jjx128","article-title":"Effect of PF-00547659 on central nervous system immune surveillance and circulating \u03b27+ T Cells in Crohn\u2019s disease: report of the TOSCA study","volume":"12","author":"D\u2019Haens","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0765","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000961","article-title":"Improvement of comorbid psoriasis in patients with MS treated with natalizumab","volume":"8","author":"Berkovich","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0770","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0033-1343797","article-title":"Alemtuzumab treatment of multiple sclerosis","volume":"33","author":"Coles","year":"2013","journal-title":"Semin Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0775","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T","article-title":"Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia","volume":"44","author":"Isaacs","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0780","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13075-016-1188-6","article-title":"Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies","volume":"18","author":"Cooles","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0785","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes038","article-title":"Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses","volume":"51","author":"Anderson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"17","key":"10.1016\/j.autrev.2023.103312_bb0790","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"CAMMS223 Trial Investigators","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2023.103312_bb0795","first-page":"1589","article-title":"CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis","volume":"38","author":"Weinblatt","year":"1995","journal-title":"An intravenous dose-escalation study. Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0800","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","article-title":"CAMPATH-1H in rheumatoid arthritis\u2014an intravenous dose-ranging study","volume":"35","author":"Isaacs","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0805","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb0810","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/qjmed\/89.12.903","article-title":"Treatment of refractory Wegener\u2019s granulomatosis with humanized monoclonal antibodies","volume":"89","author":"Lockwood","year":"1996","journal-title":"QJM"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0815","first-page":"473","article-title":"Refractory Wegener\u2019s granulomatosis: a model for shorter immunotherapy of autoimmune diseases","volume":"32","author":"Lockwood","year":"1998","journal-title":"J R Coll Physicians Lond."},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0820","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/RHU.0b013e318284735c","article-title":"Remission induction in a case of refractory Beh\u00e7et disease with alemtuzumab","volume":"19","author":"Perez-Pampin","year":"2013","journal-title":"J Clin Rheumatol"},{"issue":"8861","key":"10.1016\/j.autrev.2023.103312_bb0825","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/0140-6736(93)90759-A","article-title":"Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy","volume":"341","author":"Lockwood","year":"1993","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb0830","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard.2007.081661","article-title":"Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)","volume":"67","author":"Walsh","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb0835","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as remission induction therapy in beh\u00e7et disease: a 20-year experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0840","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13075-022-02761-6","article-title":"Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)","volume":"24","author":"Gopaluni","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"Pt 6","key":"10.1016\/j.autrev.2023.103312_bb0845","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0850","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/bjo.84.1.107","article-title":"Campath-1H therapy in refractory ocular inflammatory disease","volume":"84","author":"Dick","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0855","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/mi.2014.22","article-title":"T cell-associated \u03b14\u03b27 but not \u03b14\u03b21 integrin is required for the induction and perpetuation of chronic colitis","volume":"7","author":"Kurmaeva","year":"2014","journal-title":"Mucosal Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103312_bb0860","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14 \u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2023.103312_bb0865","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0870","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb0875","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0880","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0885","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","article-title":"Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0890","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s12325-020-01366-2","article-title":"Etrolizumab global steering committee. etrolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease: an overview of the phase 3 clinical program","volume":"37","author":"Sandborn","year":"2020","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0895","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"AJM300 Study Group. Safety and Efficacy of AJM300, an Oral Antagonist of \u03b14 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"issue":"3 Pt 1","key":"10.1016\/j.autrev.2023.103312_bb0900","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2004.09.029","article-title":"Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial","volume":"52","author":"Leonardi","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0905","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","article-title":"Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis","volume":"141","author":"Menter","year":"2005","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb0910","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: insights into integrin \u03b1L\u03b22 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0915","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ibd\/izx097","article-title":"What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or crohn\u2019s disease treated with vedolizumab?","volume":"24","author":"Card","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0920","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-4632.2004.02082.x","article-title":"Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia","volume":"44","author":"Abanmi","year":"2005","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0930","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nri3193","article-title":"Fine-tuning of dendritic cell biology by the TNF superfamily","volume":"12","author":"Summers Luca","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0935","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0940","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"issue":"7412","key":"10.1016\/j.autrev.2023.103312_bb0945","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb0950","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2249.2011.04484.x","article-title":"Role of tumour necrosis factor (TNF)-\u03b1 and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis","volume":"166","author":"Caminero","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0955","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/187153006779025694","article-title":"Anti-interleukin-6 receptor antibody therapy in rheumatic diseases","volume":"6","author":"Nakahara","year":"2006","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0960","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/18756190MTA2cMjAm1","article-title":"Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: a systematic review of safety and efficacy","volume":"19","author":"Lotan","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"17","key":"10.1016\/j.autrev.2023.103312_bb0965","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb0970","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/nmt-2020-0046","article-title":"Satralizumab in the treatment of neuromyelitis optica spectrum disorder","volume":"11","author":"Duchow","year":"2021","journal-title":"Neurodegener Dis Manag"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb0975","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103312_bb0980","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211041854","article-title":"Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence","volume":"13","author":"Braun","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb0985","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb0990","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb0995","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb1000","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3899\/jrheum.201111","article-title":"Secukinumab efficacy on enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal phase III studies","volume":"48","author":"Schett","year":"2021","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1005","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00415-016-8128-x","article-title":"Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study","volume":"263","author":"Havrdov\u00e1","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1358\/dot.2010.46.4.1464839","article-title":"Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials","volume":"46","author":"Farhi","year":"2010","journal-title":"Drugs Today (Barc)"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1025","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/17474124.2016.1215912","article-title":"Ustekinumab for the treatment of Crohn\u2019s disease","volume":"10","author":"Hansen","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/14737175.9.3.319","article-title":"Why did IL-12\/IL-23 antibody therapy fail in multiple sclerosis?","volume":"9","author":"Longbrake","year":"2009","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb1050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165248","article-title":"IL-12\/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation","volume":"11","author":"Cravens","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb1055","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.4049\/jimmunol.147.8.2461","article-title":"CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells","volume":"147","author":"Jenkins","year":"1991","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1060","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4049\/jimmunol.157.4.1333","article-title":"CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis","volume":"157","author":"Perrin","year":"1996","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1065","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.autrev.2023.103312_bb1070","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"issue":"9636","key":"10.1016\/j.autrev.2023.103312_bb1075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1080","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2023.103312_bb1085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0165-5728(99)00072-7","article-title":"The CTLA-4 gene is associated with multiple sclerosis","volume":"97","author":"Ligers","year":"1999","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb1090","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/1352458516662727","article-title":"ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis","volume":"23","author":"Khoury","year":"2017","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2023.103312_bb1095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1387-2656(06)12006-2","article-title":"Inhibitors of signal transduction protein kinases as targets for cancer therapy","volume":"12","author":"Mikalsen","year":"2006","journal-title":"Biotechnol Annu Rev"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1100","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00018-008-8539-7","article-title":"Therapeutic protein kinase inhibitors","volume":"66","author":"Grant","year":"2009","journal-title":"Cell Mol Life Sci"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2023.103312_bb1105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(98)00066-7","article-title":"Protein tyrosine kinase inhibitors as novel therapeutic agents","volume":"82","author":"Levitzki","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1359-6446(03)03014-9","article-title":"Inhibitors of JAKs\/STATs and the kinases: a possible new cluster of drugs","volume":"9","author":"Luo","year":"2004","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1115","doi-asserted-by":"crossref","first-page":"e1148","DOI":"10.1212\/NXI.0000000000001148","article-title":"AB07002 study group. efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, Phase 3, Clinical Trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"24","key":"10.1016\/j.autrev.2023.103312_bb1120","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0024-3205(98)00538-4","article-title":"Janus kinases and their role in growth and disease","volume":"64","author":"Aringer","year":"1999","journal-title":"Life Sci"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2023.103312_bb1125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(00)00018-3","article-title":"The Jak-STAT pathway","volume":"37","author":"Imada","year":"2000","journal-title":"Mol Immunol"},{"issue":"21","key":"10.1016\/j.autrev.2023.103312_bb1130","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1038\/sj.onc.1203550","article-title":"Pharmaceutical intervention in the JAK\/STAT signaling pathway","volume":"19","author":"Seidel","year":"2000","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"9865","key":"10.1016\/j.autrev.2023.103312_bb1145","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.autrev.2023.103312_bb1150","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.autrev.2023.103312_bb1155","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in Patients with Refractory Rheumatoid Arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1160","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"10139","key":"10.1016\/j.autrev.2023.103312_bb1165","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"10139","key":"10.1016\/j.autrev.2023.103312_bb1170","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"10188","key":"10.1016\/j.autrev.2023.103312_bb1175","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.autrev.2023.103312_bb1180","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"10315","key":"10.1016\/j.autrev.2023.103312_bb1190","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1195","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13075-021-02590-z","article-title":"Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1200","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.autrev.2023.103312_bb1205","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb1210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"16","key":"10.1016\/j.autrev.2023.103312_bb1220","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.autrev.2023.103312_bb1225","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb1240","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb1245","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"10214","key":"10.1016\/j.autrev.2023.103312_bb1250","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1255","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10290","key":"10.1016\/j.autrev.2023.103312_bb1265","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"10290","key":"10.1016\/j.autrev.2023.103312_bb1270","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb1275","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb1280","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"18","key":"10.1016\/j.autrev.2023.103312_bb1285","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1290","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb1295","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/acscombsci.0c00169","article-title":"Activity prediction of small molecule inhibitors for antirheumatoid arthritis targets based on artificial intelligence","volume":"22","author":"Xing","year":"2020","journal-title":"ACS Comb Sci"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb1300","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/13543784.2020.1807934","article-title":"Inhibition of Bruton\u00b4s tyrosine kinase as a novel therapeutic approach in multiple sclerosis","volume":"29","author":"Torke","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1305","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","article-title":"Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases","volume":"64","author":"Xie","year":"2021","journal-title":"J Med Chem"},{"issue":"37","key":"10.1016\/j.autrev.2023.103312_bb1310","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.1021\/acs.jafc.0c03369","article-title":"Diaryl ether: a privileged scaffold for drug and agrochemical discovery","volume":"68","author":"Chen","year":"2020","journal-title":"J Agric Food Chem"},{"issue":"47","key":"10.1016\/j.autrev.2023.103312_bb1315","article-title":"Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy","volume":"1","author":"Liu","year":"2021","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb1320","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton\u2019s Tyrosine Kinase Inhibition Promotes Myelin Repair","volume":"5","author":"Martin","year":"2020","journal-title":"Brain Plast"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1325","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/1381612827666210701152934","article-title":"Bruton\u2019s Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis","volume":"28","author":"Steinmaurer","year":"2022","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1330","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(21)00250-7","article-title":"BTK inhibitors as potential therapies for multiple sclerosis","volume":"20","author":"Correale","year":"2021","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103312_bb1335","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005926","article-title":"Second messengers","volume":"8","author":"Newton","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1340","first-page":"123","article-title":"The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases","volume":"31","author":"Raker","year":"2016","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1345","first-page":"4","article-title":"PDE-mediated cyclic nucleotide compartmentation in vascular smooth muscle cells: from basic to a clinical perspective","volume":"9","author":"Lorigo","year":"2021","journal-title":"J Cardiovasc Dev Di."},{"issue":"7135","key":"10.1016\/j.autrev.2023.103312_bb1350","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature05698","article-title":"Epithelial NEMO links innate immunity to chronic intestinal inflammation","volume":"446","author":"Nenci","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0968-0004(97)01050-5","article-title":"Tailoring cAMP-signalling responses through isoform multiplicity","volume":"22","author":"Houslay","year":"1997","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1360","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jlb.63.1.101","article-title":"Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production","volume":"63","author":"Eigler","year":"1998","journal-title":"J Leukoc Biol"},{"issue":"1 Pt 1","key":"10.1016\/j.autrev.2023.103312_bb1365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0091-6749(97)81041-X","article-title":"Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression","volume":"99","author":"Essayan","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1370","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20062129","article-title":"Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression","volume":"204","author":"Bopp","year":"2007","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb1375","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pupt.2004.10.001","article-title":"The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro","volume":"18","author":"Jones","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.autrev.2023.103312_bb1380","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"MN166-001 Investigators. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1385","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"NN102\/SPRINT-MS Trial Investigators. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1390","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/1352458520964409","article-title":"Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis","volume":"27","author":"Bermel","year":"2021","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1395","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1212\/WNL.0000000000011314","article-title":"SPRINT-MS investigators. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study","volume":"96","author":"Naismith","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1400","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acn3.51251","article-title":"SPRINT-MS Investigators. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype","volume":"8","author":"Goodman","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"13","key":"10.1016\/j.autrev.2023.103312_bb1405","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1177\/1352458520986956","article-title":"Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103312_bb1415","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.20083","article-title":"Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study","volume":"185","author":"Van Voorhees","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1420","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study","volume":"83","author":"Van Voorhees","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1425","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1430","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103312_bb1435","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1440","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb1445","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","article-title":"ACTIVE investigators. Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb1450","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1455","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.berh.2013.07.011","article-title":"Pulmonary hypertension in systemic lupus erythematosus","volume":"27","author":"Schreiber","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1460","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103312_bb1465","doi-asserted-by":"crossref","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","article-title":"Apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","volume":"132","author":"Hatemi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103312_bb1470","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/mr\/roab008","article-title":"Apremilast in a Japanese subgroup with Beh\u00e7et\u2019s syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study","volume":"32","author":"Takeno","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"20","key":"10.1016\/j.autrev.2023.103312_bb1475","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for Oral Ulcers in Beh\u00e7et\u2019s Syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1480","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1485","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial","volume":"86","author":"Saeki","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103312_bb1490","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial","volume":"186","author":"Saeki","year":"2022","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb1495","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.clinthera.2012.11.006","article-title":"GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study","volume":"34","author":"Curtin","year":"2012","journal-title":"Clin Ther"},{"issue":"8745","key":"10.1016\/j.autrev.2023.103312_bb1500","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0140-6736(91)92579-Q","article-title":"Isolation of retrovirus from patients with multiple sclerosis","volume":"337","author":"Perron","year":"1991","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.autrev.2023.103312_bb1505","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1177\/1352458510376956","article-title":"Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis","volume":"16","author":"Sotgiu","year":"2010","journal-title":"Mult Scler"},{"issue":"Pt 1","key":"10.1016\/j.autrev.2023.103312_bb1510","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1099\/vir.0.81890-0","article-title":"Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus\/HERV-W endogenous retrovirus, but not Human herpesvirus 6","volume":"88","author":"Mameli","year":"2007","journal-title":"J Gen Virol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103312_bb1515","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1177\/1352458512441381","article-title":"Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease","volume":"18","author":"Perron","year":"2012","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.autrev.2023.103312_bb1520","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.clinthera.2019.05.020","article-title":"A High-dose pharmacokinetic study of a new IgG4 monoclonal antibody temelimab\/GNbAC1 antagonist of an endogenous retroviral protein pHERV-W Env","volume":"41","author":"Porchet","year":"2019","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.autrev.2023.103312_bb1525","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1352458514554052","article-title":"A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients","volume":"21","author":"Derfuss","year":"2015","journal-title":"Mult Scler"},{"issue":"285","key":"10.1016\/j.autrev.2023.103312_bb1530","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2015.05.019","article-title":"A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up","volume":"15","author":"Derfuss","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103312_bb1535","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/13524585211024997","article-title":"Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study","volume":"28","author":"Hartung","year":"2022","journal-title":"Mult Scler"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:30:38Z","timestamp":1761600638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":307,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1568997223000460"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103312","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103312"}}